All Posts

emerging-therapies-for-non-muscle-invasive-bladder-cancer-treatment
Advances in Non-Muscle Invasive Bladder Cancer Treatment: Exploring Emerging Therapies

Non-muscle-invasive bladder cancer represents a category of bladder cancer where the tumor is confined to the innermost layer of the bladder lining without invading the muscle. This early-stage form accounts for a significant proportion of bladder cancer cases. Among the 7MM, the US accounted for the highest num...

Find More

egfr-inhibitors-for-cancer-treatment
Potential of EGFR Inhibitors: A Promising Avenue in Cancer Treatment

In the realm of cancer treatment, the development of targeted therapies has been nothing short of revolutionary. Among these advancements, EGFR inhibitors have emerged as a powerful weapon in the fight against certain types of cancer. EGFR, or Epidermal Growth Factor Receptor, is a protein found on the surface of c...

Find More

medtech-news-for-tela-bio-stryker-livanova-c2dx
TELA Bio Launched Hernia Mesh Fixation Devices; Stryker Acquisition of SERF SAS; FDA 510(k) Clearance for RedDrop Dx’s Blood Collection Device; FDA 510(k) Clearance for Next Generation Shaw Scalpel; LivaNova’s Sleep Apnoea Device Trial; Nanodropper’s Positive Impact on Glaucoma Treatment

TELA Bio Launched FDA-approved Hernia Mesh Fixation Devices  On March 21, 2024, TELA Bio, Inc., a medical technology firm, launched its FDA-approved LIQUIFIX devices for hernia repairs in the United States. The LIQUIFIX FIX8™ and LIQUIFIX Precision™ are specifically engineered for laparoscopic and open femo...

Find More

herbal-medicine-market-assessment
Botanical Bounty: Cracking the Herbal Medicine Market Enigma and Growth Potential

Herbal Medicine, rooted in ancient traditions across cultures worldwide, has witnessed a remarkable evolution in the modern era. The global Herbal Medicine Market has experienced significant growth over the years, fueled by a resurgence of interest in natural remedies and a growing awareness of the potential health...

Find More

pharma-news-for-regeneron-novartis-novo-nordisk-abbvie
Regeneron’s Odronextamab BLA; Novo Nordisk’s Cardior Pharmaceuticals Acquisition; Novartis’ Fabhalta CHMP Approval; Idorsia’s TRYVIO FDA Approval; AbbVie’s Landos Biopharma Acquisition

Regeneron Updates Progress on Biologics License Application for Odronextamab Regeneron Pharmaceuticals, Inc. has announced that the FDA has issued Complete Response Letters (CRLs) regarding the Biologics License Application (BLA) for odronextamab in cases of relapsed/refractory (R/R) follicular lymphoma (FL) and...

Find More

gene-therapies-for-epidermolysis-bullosa-treatment
Gene Therapies for Epidermolysis Bullosa Treatment: The Next Frontier in Dermatology

Epidermolysis bullosa is a genetic skin condition marked by severe skin sensitivity and the formation of blisters even from minor friction or injury. This disorder arises from genetic changes that impact the proteins crucial for upholding the skin’s structural strength. The degree of severity in epidermolysis bullo...

Find More

rezdiffra-for-nash-treatment
Madrigal’s Rezdiffra Breakthrough Transforms NASH Treatment, Leading the Way for Next-Gen Therapies

The prolonged wait for an effective remedy for non-alcoholic steatohepatitis (NASH) has concluded with the FDA’s approval of the inaugural drug for this fatty liver condition. Madrigal Pharmaceuticals’ resmetirom, soon available as Rezdiffra, has achieved the milestone of becoming the primary therapy for NASH to re...

Find More

medtech-news-for-vygon-butterfly-network-cosm-medical
Vygon Launched Nutrisafe2 System; Butterfly Network Launched Third-Gen Ultrasound; Cosm Medical Won FDA Clearance; FDA Cleared Sequel Med Tech Automated Insulin Delivery System; IceCure Medical Reported Positive Topline Results; Cerus Announced Positive Results in Blood Purification Trial

Vygon Launched Neonatal Safety in India with Groundbreaking Nutrisafe2 System  On March 15, 2024, Vygon, a leader in the production and marketing of specialized medical equipment, introduced Nutrisafe2, a technological leap forward. This state-of-the-art enteral feeding device for neonates guarantees the sa...

Find More

digestive-health-products-key-factors-and-market-dynamics
Digestive Health Products: Exploring the Market Dynamics and Key Factors Driving the Demand

Over the years, the landscape of Digestive Health Products has undergone significant evolution driven by advancements in scientific understanding, changing consumer preferences, and emerging market trends. As per the latest study by DelveInsight, the global Digestive Health Products market was valued at USD 39,345....

Find More

pharma-news-for-bms-orchard-madrigal-astrazeneca
Bristol Myers Squibb’ Karuna Therapeutics Buyout; Orchard Therapeutics’ Lenmeldy FDA Approval; Madrigal Pharmaceuticals’ Rezdiffra FDA Approval; AstraZeneca’s Acquisition of Amolyt Pharma; Prilenia’s Pridopidine EU Marketing Approval

Bristol Myers Squibb Enhances Neuroscience Arm with Karuna Therapeutics Buyout Bristol Myers Squibb has declared the finalization of its purchase of Karuna Therapeutics, Inc. With this acquisition concluded Karuna’s shares are no longer being traded on the Nasdaq Global Select Market, as Karuna is now fully owne...

Find More